The approval of dabigatran (Pradaxa) has been long awaited in the cardiology community. Although just about everyone agrees that a good alternative to warfarin is highly desirable, there are many remaining questions about the drug as it prepares to enter the marketplace.Here are a few questions raised by electrophysiologist John Mandrola on his blog:
- In the RE-LY trial, dabigatran was used twice daily. When not symptomatic, patients ...





